Erratum: T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells (Cancer Cell (2016) 30(3) (377–390)(S1535610816303890)(10.1016/j.ccell.2016.08.004))

(Cancer Cell 30, 377–390; September 12, 2016) In the originally published version of this paper, the authors mistakenly used the incorrect acronym of the mouse strain in the legend of Figure 5B: “CFSE-labeled polyclonal CD8⁺ T cells specific for OVA were derived from immunized WT or E8l^cre × Cd40lg^flox/flox mice and were incubated with EG7 tumor slices from either WT or CD40L KO mice, as indicated.” The corrected sentence now reads as follows: “CFSE-labeled polyclonal CD8⁺ T cells specific for OVA were derived from immunized WT or CD40L KO mice and were incubated with EG7 tumor slices from either WT or CD40L KO mice, as indicated.” This error has now been corrected in the original paper online. While this correction does not affect the findings or conclusions of the study, the authors would like to apologize for this error and any confusion that it may have caused the readers.